Momenta’s Generic Lovenox Suit Is Harbinger Of Biosimilar Battles Over Manufacturing

Momenta Pharmaceuticals Inc.’s battle to keep other versions of generic Lovenox (enoxaparin) off the market is a forerunner of disputes that will hit the courts once FDA begins to approve biosimilars.

On Oct. 28, a Massachusetts federal court issued a preliminary injunction preventing Amphastar Pharmaceuticals Inc. and its marketing partner...

More from Archive

More from Pink Sheet